This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Age 40-84 years (both inclusive) at the time of signing the informed consent
Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening
Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation
Left ventricular ejection fraction ≥50% as assessed by echocardiography at screening, measured by central laboratory
Estimated glomerular filtration rate lesser than (<) 30 milliliter per minute (mL/min)/1.73 square meter (m²) at time of screening, measured by central laboratory
Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation
Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening
Participants receiving intravenous HF medications within 45 days prior to randomisation